Want to join the conversation?
$SUPN said it is in talks with the FDA on sNDA for migraine. The FDA had asked $SUPN to resubmit the Trokendi XR product label with migraine as an indication prior to completing its review. Company will resubmit the revised label before end June. For 2016, $SUPN expects net product sales to be $200-210MM and operating income to be $28-35MM.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!